MindWalk Holdings Corp. (HYFT) stock
HYFTNasdaqPharmaceutical PreparationsFiscal year ends April 30
$0.99−0.01 (-1.00%)
Close on Nov 13, 2026Market cap $46.24MP/E –Yield –
MindWalk EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.91 CAD. The highest annual figure on record is -0.36 CAD in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | -0.91 CAD | – |
| FY2024 | Apr 30, 2024 | -1.02 CAD | – |
| FY2023 | Apr 30, 2023 | -1.07 CAD | – |
| FY2022 | Apr 30, 2022 | -0.85 CAD | – |
| FY2021 | Apr 30, 2021 | -0.45 CAD | – |
| FY2020 | Apr 30, 2020 | -0.36 CAD | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025CQ4 2024 | Jan 31, 2025 | -0.66 CAD | – |
| Q2 FY2025CQ3 2024 | Oct 31, 2024 | -0.09 CAD | – |
| Q1 FY2025CQ2 2024 | Jul 31, 2024 | -0.15 CAD | – |
| Q3 FY2024CQ4 2023 | Jan 31, 2024 | -0.10 CAD | – |
| Q2 FY2024CQ3 2023 | Oct 31, 2023 | -0.10 CAD | – |
| Q1 FY2024CQ2 2023 | Jul 31, 2023 | -0.14 CAD | – |
| Q3 FY2023CQ4 2022 | Jan 31, 2023 | -0.19 CAD | – |
| Q2 FY2023CQ3 2022 | Oct 31, 2022 | -0.30 CAD | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?